表紙
市場調查報告書
商品編碼
1078291

阿茲海默症的生物標記臨床試驗市場:2028年

Alzheimer's Disease Biomarkers and Clinical Trials Insight 2028

出版日期: | 出版商: Biomarkers Insights | 英文 900 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球阿茲海默症的生物標記臨床試驗市場相關調查,市場概要,以及阿茲海默症的概要與已核准藥物,新興治療方法,臨床試驗趨勢,及加入此市場的主要企業的競爭情形等資訊。

目錄

第1章 全球阿茲海默症治療藥市場分析

  • 目前市場趨勢
  • 各地區市場情境
  • 未來市場機會

第2章 核准完畢阿茲海默症治療藥:各級

  • 膽鹼酯酶抑制劑
  • NMDA受體激動劑

第3章 阿茲海默症的新興治療方法

  • 單株抗體
  • 新NMDA受體激動劑
  • 低分子藥
  • 口服Semaglutide

第4章 乙醯膽鹼酯酶抑制劑:市場上的可得性,劑量,專利及價格的洞察

  • Razadyne
  • Razadyne ER
  • Aricept
  • Aricept ODT
  • Reminyl
  • Exelon
  • Citicoline
  • Aldarity

第5章 N-甲基-D-天冬氨酸抑制劑:市場上的可得性,劑量,專利及價格的洞察

  • Namenda
  • Namenda XR
  • Ebixa

第6章 治療用抗體:市場上的可得性,劑量及價格的洞察

  • Aducanumab (Aduhelm)

第7章 並用藥:市場上的可得性,劑量及價格的洞察

  • Namzaric

第8章 阿茲海默症的認證完畢學名藥:市場上的可得性,劑量及價格的洞察

  • Galantamine
  • Donepezil
  • Rivastigmine
  • Memantine
  • Ergoloid Mesylates

第9章 其他的藥物:市場上的可得性,劑量及價格的洞察

  • Suvorexant (Belsomra)
  • 維他命E
  • Sulbutiamine
  • Piracetam
  • Sodium Oligomannate

第10章 全球阿茲海默症治療藥的臨床試驗概要

  • 各生物市場
  • 各處方
  • 各組織
  • 各相
  • 各患者市場區隔

第11章 阿茲海默症的藥物生物標記的洞察,各臨床試驗階段

第12章 市售的阿茲海默症的藥物生物標記的洞察

第13章 競爭情形

  • Allergan
  • Alvogen
  • Dr. Reddy Laboratories
  • Eisai Co Ltd
  • Hoffmann-La Roche Ltd
  • Jassen Pharmaceuticals
  • Lupin
  • Mylan
  • Novartis AG
  • Sun Pharma
  • Teva Pharmaceuticals
目錄

“Alzheimer's Disease Biomarkers and Clinical Trials Insight 2028” Report Highlights:

  • Global Alzheimer's Disease Antibodies Market Opportunity: > USD 5 Billion
  • Alzheimer's Disease Clinical Trials Insight: > 200 Drugs In Trials
  • Alzheimer's Disease Biomarkers Sourced During Clinical Trials
  • Alzheimer's Disease Insight By Classification
  • Insight On Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Drug
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

With the rapid ageing of world's population, there is significant rise in the prevalence of dementia associated with Alzheimer disease. The prevalence of Alzheimer disease has become a major social issue as it affects the length and quality of patient's life and the physiological and economic status of patients and their families. Presently available Alzheimer disease drugs have been unable to halt the progression of Alzheimer disease. Therefore, researchers believed that early diagnosis and prevention of Alzheimer disease is of utmost important to reduce severity and enhance prognosis of the disease.

Therefore, the search for potential clinical biomarkers in Alzheimer disease is one of the hottest areas of research among scientists. The biomarkers identified should be specific, suitable for routine use in clinical practice, and indicate specific stages of the disease. Currently, the most-cited blood and CSF biomarkers for diagnosing Alzheimer disease include the 42-amino acid form of amyloid-beta peptide (Ab1-42), the Ab1-42/Ab1-40 ratio, total and phosphorylated fractions of tau proteins (T-Tau and P-Tau, respectively), neurofilament light chain (NFL) protein, phosphorylated tau at position threonine 181 (P-Tau 181), and 217 (P-Tau217). Apart from this, several ongoing clinical studies are also evaluating other potential biomarkers which can aid in development of diagnostic test or novel targeted therapy for Alzheimer disease.

Recently researchers at Mayo Clinic have identified a new set of markers in blood plasma. This discovery could lead to the development of improved diagnostic tests for Alzheimer's disease. The study focuses on the RNA molecules which are present in plasma as potential biomarkers for the Alzheimer's disease in African Americans. The study builds on previous research that identified genetic risk factors for Alzheimer's disease and established that RNA molecules in blood plasma could potentially be used as biomarkers. This research demonstrates that this discovery could lead to more accurate Alzheimer's disease screening for everyone, particularly for the people and communities at greatest risk.

Traditionally, the detection of disease-causing pathology associated with Alzheimer's disease and Vascular Contributions to Cognitive Impairment and Dementia (VCID) is limited to cognitive evaluations and neuroimaging like MRI and PET scans. To mitigate the challenges associated with conventional detection methods, researchers have identified several blood biomarkers, which can be beneficial in the diagnosis of Alzheimer's and other dementias. The study demonstrated that higher pTau181 and lower beta-amyloid in the blood indicate amyloid plaques of Alzheimer's in the brain. Further, researchers also found that inflammation proteins in blood were related to damage to blood vessels in the brain. It is suggested that advancements in research regarding biomarkers will allow physicians to detect changes in brain, monitor the disease's progression, and test the effectiveness of potential treatments.

As per our report findings, the global Alzheimer disease drug market is expected to surpass US$ 5 Billion by 2028 which is mainly attributed to the rise in prevalence of Alzheimer disease. US is expected to hold a dominant share in the global market over the forecast period, owing to rising government initiatives for management of Alzheimer disease, rising awareness among population for early diagnosis of disease, and presence of strong research and development sector. Moreover the rising focus of market players in business strategies such as acquisitions, partnerships, and others are expected to fuel the growth of Alzheimer disease biomarkers market over the forecast period.

The report provides in-depth analysis on more than 100 biomarkers which are present in clinical trials across various drugs for Alzheimer disease. The report presents detailed analyses of the key market trends, drivers and opportunities, market size and forecasts, top investment pockets, and competitive landscape. Strategies recorded by the key players are analyzed thoroughly to understand the competitive outlook of the market.

Table of Contents

1. Global Alzheimer Drug Market Analysis

  • 1.1 Current Market Trends
  • 1.2 Regional Market Scenario
  • 1.3 Future Market Opportunity

2. Approved Alzheimer's Disease Drugs by Class

  • 2.1 Cholinesterase Inhibitors
  • 2.2 NMDA Receptor Agonist

3. New Emerging Therapies in Alzheimer's Disease

  • 3.1 Monoclonal Antibody
  • 3.2 Novel NMDA Receptor Agonists
  • 3.3 Small Molecules Drug
  • 3.4 Oral Semaglutide

4. Acetylcholinesterases Inhibitor: Market Availability, Dosage, Patent & Price Insight

  • 4.1 Razadyne
  • 4.2 Razadyne ER
  • 4.3 Aricept
  • 4.4 Aricept ODT
  • 4.5 Reminyl
  • 4.6 Exelon
  • 4.7 Citicoline
  • 4.8 Aldarity

5. N-methyl-D-aspartate Inhibitors: Market Availability, Dosage, Patent & Price Insight

  • 5.1 Namenda
  • 5.2 Namenda XR
  • 5.3 Ebixa

6. Therapeutic Antibodies: Market Availability, Dosage & Price Insight

  • 6.1 Aducanumab (Aduhelm)

7. Combinational Drugs: Market Availability, Dosage & Price Insight

  • 7.1 Namzaric

8. Approved Generic Drugs for Alzheimer's: Market Availability, Dosage & Price Insight

  • 8.1 Galantamine
  • 8.2 Donepezil
  • 8.3 Rivastigmine
  • 8.4 Memantine
  • 8.5 Ergoloid Mesylates

9. Other Drugs: Market Availability, Dosage & Price Insight

  • 9.1 Suvorexant (Belsomra)
  • 9.2 Vitamin E
  • 9.3 Sulbutiamine
  • 9.4 Piracetam
  • 9.5 Sodium Oligomannate

10. Global Alzheimer's Disease Drugs Clinical Trials Overview

  • 10.1 By Biomarket
  • 10.2 By Formulation
  • 10.3 By Organization
  • 10.4 By Phase
  • 10.5 By Patient Segment

11. Alzheimer's Drug Biomarker Insight By Clinical Trials Phase

  • 11.1 Research
  • 11.2 Preclinical
  • 11.3 Clinical
  • 11.4 Phase-I
  • 11.5 Phase-I/II
  • 11.6 Phase-II
  • 11.7 Phase-II/III
  • 11.8 Phase-III
  • 11.9 Preregistration
  • 11.10 Registered

12. Marketed Alzheimer's Drug Biomarker Insight

13. Competitive Landscape

  • 13.1 Allergan
  • 13.2 Alvogen
  • 13.3 Dr. Reddy Laboratories
  • 13.4 Eisai Co Ltd
  • 13.5 Hoffmann- La Roche Ltd
  • 13.6 Jassen Pharmaceuticals
  • 13.7 Lupin
  • 13.8 Mylan
  • 13.9 Novartis AG
  • 13.10 Sun Pharma
  • 13.11 Teva Pharmaceuticals

List of Figures

  • Figure 1-1: Global - Alzheimer Disease Market Size (US$ Billion), 2020 & 2021
  • Figure 1-2: US vs. ROW - Alzheimer Disease Market (US$ Billion), 2021
  • Figure 1-3: US vs. ROW - Alzheimer Disease Market (%), 2021
  • Figure 1-4: Alzheimer Disease Market Size by Region (US$ Billion), 2021
  • Figure 1-5: Alzheimer Disease Market Size by Region (%), 2021
  • Figure 1-6: Global - Alzheimer Disease Market Size (US$ Billion), 2022 - 2028
  • Figure 1-7: US - Alzheimer Disease Market Size (US$ Billion), 2022 - 2028
  • Figure 2-1: Acetylcholinesterase Inhibitors - Mechanism of Action
  • Figure 2-2: Memantine - Mode of Action
  • Figure 3-1: Designed Monoclonal Antibodies for Alzheimer Disease Discontinued Till Phase-3 Trials
  • Figure 4-1: Razadyne - FDA Approval & First Generic Approval Year
  • Figure 4-2: - Cost of Supply of 60 Tablets & Per Unit Cost of Oral Tablet (US$), March'2022
  • Figure 4-3: Razadyne- Cost of 100ml & Per Unit Cost of 4mg/ml Oral Solution (US$), March'2022
  • Figure 4-4: Razadyne - Recommended Initial Dose & Incremented Dose (mg/day)
  • Figure 4-5: Razadyne - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 4-6: Razadyne ER - FDA Approval & First Generic Approval Year
  • Figure 4-7: Razadyne ER - Cost of 30 Capsules & Per Unit Cost of Extended Release Capsule (US$), March'2022
  • Figure 4-8: Razadyne ER - Recommended Initial Dose & Incremented Dose (mg/day)
  • Figure 4-9: Razadyne ER - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 4-10: Aricept - FDA Approval Year by Dosage Forms
  • Figure 4-11: Aricept - Approval Year by Region
  • Figure 4-12: US - Aricept Patent Approval & Expiration Year
  • Figure 4-13: US - Aricept FDA Approval & First Generic Approval Year
  • Figure 4-14: Europe - Aricept EMA Approval & First Generic Approval Year
  • Figure 4-15: US - Cost of 30 Tablets & Per Unit Cost of Aricept 5mg Oral Tablets (US$), March'2022
  • Figure 4-16: US - Cost of 30 Tablets & Per Unit Cost of Aricept 10mg Oral Tablets (US$), March'2022
  • Figure 4-17: US - Cost of 21 Tablets & Per Unit Cost of Aricept 10mg Oral Tablets (US$), March'2022
  • Figure 4-18: US - Cost of 30 Tablets & Per Unit Cost of Aricept 23mg Oral Tablets (US$), March'2022
  • Figure 4-19: UK - Cost of 28 Tablets & Per Unit Cost of Aricept 5mg Oral Tablets (GBP/US$), March'2022
  • Figure 4-20: UK - Cost of 28 Tablets & Per Unit Cost of Aricept 10mg Oral Tablets (GBP/US$), March'2022
  • Figure 4-21: Aricept - Recommended & Incremented Dose for Alzheimer's disease (mg/day)
  • Figure 4-22: Aricept - Time Interval for 1st & 2nd Dose Increment (Weeks)
  • Figure 4-23: Aricept - Recommended Minimum & Maximum Dose (mg/day),
  • Figure 4-24: Aricept ODT - Cost of 30 Tablets & Per Unit Cost of 5mg Oral Tablet (US$), March'2022
  • Figure 4-25: Aricept ODT - Cost of 30 Tablets & Per Unit Cost of 10mg Oral Tablet (US$), March'2022
  • Figure 4-26: Aricept ODT - Recommended Initial & Incremented Dose (mg/day)
  • Figure 4-27: Aricept ODT - Time Interval Required for Dose Increment (Weeks)
  • Figure 4-28: Reminyl - Approval Year by Region
  • Figure 4-29: UK - Cost of 100ml & Per Unit Cost of Reminyl 4mg/ml Oral Solution (GBP/US$), March'2022
  • Figure 4-30: UK - Cost of 28 Capsules & Per Unit Cost of Reminyl 8mg Oral Capsules (GBP/US$), March'2022
  • Figure 4-31: UK - Cost of 28 Capsules & Per Unit Cost of Reminyl 16mg Oral Capsules (GBP/US$), March'2022
  • Figure 4-32: UK - Cost of 28 Capsules & Per Unit Cost of Reminyl 24mg Oral Capsuless (GBP/US$), March'2022
  • Figure 4-33: Reminyl - Recommended Initial & Incremented Dose (mg/day)
  • Figure 4-34: Exelon - Approval Year by Region
  • Figure 4-35: Exelon - FDA Approval Year by Dosage Forms
  • Figure 4-36: Exelon - FDA Approval & 1st Generic Approval Year
  • Figure 4-37: US - Cost of Supply of 30 Films & Per Unit Cost of Exelon Transdermal Film Extended Release (US$), March'2022
  • Figure 4-38: UK - Cost of Supply of 30 Films & Per Unit Cost of Exelon Transdermal Film Extended Release (GBP/US$), March'2022
  • Figure 4-39: Exelon - Recommended Initial & Incremented Dose (mg/24 Hours)
  • Figure 4-40: India - Cost of Supply of 10 Tablets & Per Unit Cost of Strocit Oral Tablet (INR/US$), March'2022
  • Figure 4-41: India - Cost of Supply of Strocit Injection by Quantity (INR/US$), March'2022
  • Figure 4-42: India - Cost of Supply of 10 Tablets & Per Unit Cost of Clinaxon Oral Tablet (INR/US$), March'2022
  • Figure 4-43: India - Cost of Supply of Clinaxon Injection by Quantity (INR/US$), March'2022
  • Figure 4-44: Citicoline - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 4-45: Aldarity - Recommended Initial & Maximum Dose (mg/day)
  • Figure 5-1: Namenda - Approval Year by Region
  • Figure 5-2: Namenda - FDA Approval Year by Dosage Forms
  • Figure 5-3: Namenda - FDA Approval & First Generic Approval Year
  • Figure 5-4: US - Cost of Supply of 49 Kits & Per Unit Cost of Namenda Oral Kit (US$), March'2022
  • Figure 5-5: US - Cost of Supply of 60 Tablets & Per Unit Cost of Namenda Oral Tablets (US$), March'2022
  • Figure 5-6: US - Cost of Supply of 100 Tablets & Per Unit Cost of Namenda Oral Tablets (US$), March'2022
  • Figure 5-7: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Nemdatine 10mg Oral Tablet (GBP/US$), March'2022
  • Figure 5-8: Namenda - Recommended Initial & Incremented Dose (mg/day)
  • Figure 5-9: Namenda - Minimum & Maximum Recommended Dose (mg/day)
  • Figure 5-10: Namenda XR/ Memantine Merz - Approval Year by Region
  • Figure 5-11: Namenda XR - FDA Approval & First Generic Approval Year
  • Figure 5-12: US - Namenda XR Patent Approval & Expiration Year
  • Figure 5-13: US - Cost of Supply of 30 Capsules & Per Unit Cost of Namenda XR Oral Capsules (US$), March'2022
  • Figure 5-14: US - Cost of Supply of 90 Capsules & Per Unit Cost of Namenda XR Oral 14mg & 21mg Capsules (US$), March'2022
  • Figure 5-15: Germany - Cost of 42 Capsules & Per Unit Cost of Memantine Merz 10mg Oral Capsules (Euro/US$), March'2022
  • Figure 5-16: Germany - Cost of 42 Capsules & Per Unit Cost of Memantine Merz 20mg Oral Capsules (Euro/US$), March'2022
  • Figure 5-17: Namenda XR - Recommended Initial & Incremented Dose (mg/day)
  • Figure 5-18: Namenda XR - Minimum & Maximum Recommended Dose (mg/day)
  • Figure 5-19: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Ebixa 10mg Oral Tablet (GBP/US$), March'2022
  • Figure 5-20: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Ebixa 20mg Oral Tablet (GBP/US$), March'2022
  • Figure 6-1: US - Cost of Supply of 1.7ml & Per Unit Price of Aduhelm Intravenous Solution (US$), March'2022
  • Figure 6-2: US - Cost of Supply of 3ml & Per Unit Price of Aduhelm Intravenous Solution (US$), March'2022
  • Figure 6-3: Aduhelm - Recommended Dose by Infusion Cycle (mg/kg)
  • Figure 6-4: Global - Aduhelm Quarterly Sales (US$ Million), Q2 - Q4'2021
  • Figure 7-1: Namzaric - FDA Approval Year by Dose
  • Figure 7-2: US - Namzaric Patent Approval & Expiration Year
  • Figure 7-3: US - Namzaric Patent Issued by Assignees
  • Figure 7-4: Namzaric - Cost of Supply of 30 Capsules & Per Unit Cost of Oral Capsule (US$), March'2022
  • Figure 7-5: Namzaric - Recommended Initial & Incremented Dose Based on Memantine Administration (mg/day)
  • Figure 7-6: Global - Namzaric Quarterly Sales (US$ Million), Q1 & Q2'2021
  • Figure 7-7: Global - Namzaric Quarterly Sales (US$ Million), Q2-Q4'2020
  • Figure 8-1: US - Cost of 30 Capsules & Per Unit Cost of 8mg Galantamine Extended Release Capsule (US$), March'2022
  • Figure 8-2: US - Cost of 30 Capsules & Per Unit Cost of 16mg Galantamine Extended Release Capsule (US$), March'2022
  • Figure 8-3: US - Cost of 30 Capsules & Per Unit Cost of 24mg Galantamine Extended Release Capsule (US$), March'2022
  • Figure 8-4: US - Cost of 100ml & Per Unit Cost of Galantamine 4mg/ml Oral Solution (US$), March'2022
  • Figure 8-5: US - Cost of Supply of 60 Tablets & Per Unit Cost of Galantamine 4mg Oral Tablet (US$), March'2022
  • Figure 8-6: US - Cost of Supply of 30 Tablets & Per Unit Cost of Galantamine Oral Tablet (US$), March'2022
  • Figure 8-7: US - Cost of Supply of 60 Tablets & Per Unit Cost of Galantamine 8mg Oral Tablet (US$), March'2022
  • Figure 8-8: US - Cost of Supply of 60 Tablets & Per Unit Cost of Galantamine 12mg Oral Tablet (US$), March'2022
  • Figure 8-9: US - Cost of Supply of 60 Galantamine Tablets by Strength (US$), March'2022
  • Figure 8-10: UK - Cost of 100ml & Per Unit Cost of Galantamine 4mg/ml Oral Solution (GBP/US$), March'2022
  • Figure 8-11: Germany - Cost of Supply of 28 Capsules & Per Unit Cost of Galantamine 8mg Oral Capsules (Euro/US$), March'2022
  • Figure 8-12: Germany - Cost of Supply of 28 Capsules & Per Unit Cost of Galantamine 16mg Oral Capsules (US$), March'2022
  • Figure 8-13: Galantamine Tablet & Solution - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-14: Galantamine ER - Recommended Initial Dose & Incremented Dose (mg/day)
  • Figure 8-15: US - Cost of Supply of 30, 90, 100, 500 & 4000 Donepezil 5mg Oral Tablets (US$), March'2022
  • Figure 8-16: US - Cost of Supply of 30, 90, 100, 500 & 2650 Donepezil 10mg Oral Tablets (US$), March'2022
  • Figure 8-17: US - Cost of 30 Tablets & Per Unit Cost of Donepezil 23mg Oral Tablets (US$), March'2022
  • Figure 8-18: US - Cost of 90 Tablets & Per Unit Cost of Donepezil 23mg Oral Tablets (US$), March'2022
  • Figure 8-19: US - Cost of 28 Tablets & Per Unit Cost of Donepezil 5mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-20: US - Cost of 30 Tablets & Per Unit Cost of Donepezil 5mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-21: US - Cost of 28 Tablets & Per Unit Cost of Donepezil 10mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-22: US - Cost of 30 Tablets & Per Unit Cost of Donepezil 10mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-23: Germany - Cost of Supply of 28 Tablets & Per Unit Cost of Donepezil 5mg Oral Tablets (Euro/US$), March'2022
  • Figure 8-24: Germany - Cost of Supply of 28 Tablets & Per Unit Cost of Donepezil 10mg Oral Tablets (Euro/US$), March'2022
  • Figure 8-25: Donepezil - Recommended & Incremented Dose for Alzheimer's disease (mg/day)
  • Figure 8-26: Donepezil - Time Interval for 1st & 2nd Dose Increment (Weeks)
  • Figure 8-27: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 1.5mg Oral Capsules (US$), March'2022
  • Figure 8-28: US - Cost of Supply of 100 Capsules & Per Unit Cost of Rivastigmine 1.5mg Oral Capsules (US$), March'2022
  • Figure 8-29: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 1.5mg Oral Capsules (US$), March'2022
  • Figure 8-30: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 3mg Oral Capsules (US$), March'2022
  • Figure 8-31: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 3mg Oral Capsules (US$), March'2022
  • Figure 8-32: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 4.5mg Oral Capsules (US$), March'2022
  • Figure 8-33: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 4.5mg Oral Capsules (US$), March'2022
  • Figure 8-34: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 6mg Oral Capsules (US$), March'2022
  • Figure 8-35: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 6mg Oral Capsules (US$), March'2022
  • Figure 8-36: US - Cost of Supply of 30 Films & Per Unit Cost of Rivastigmine 4.6mg/24hr Transdermal Film (US$), March'2022
  • Figure 8-37: US - Cost of Supply of 30 Films & Per Unit Cost of Rivastigmine 9.5mg/24hr Transdermal Film (US$), March'2022
  • Figure 8-38: US - Cost of Supply of 30 Films & Per Unit Cost of Rivastigmine 13.3mg/24hr Transdermal Film (US$), March'2022
  • Figure 8-39: UK - Cost of Supply of 28 Rivastigmine Oral Capsules by Strength (GBP/US$), March'2022
  • Figure 8-40: Rivastigmine Oral - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-41: Rivastigmine Patch- Recommended Initial & Incremented Dose (mg/24 Hours)
  • Figure 8-42: US - Cost of Supply of 30 Capsules & Per Unit Cost of Memantine 7mg Oral Capsules (US$), March'2022
  • Figure 8-43: US - Cost of Supply of 100 Capsules & Per Unit Cost of Memantine 7mg Oral Capsules (US$), March'2022
  • Figure 8-44: US - Cost of Supply of 30, 90, & 100 Capsules of Memantine 14mg Oral Capsules (US$), March'2022
  • Figure 8-45: US - Cost of Supply of 30 Capsules & Per Unit Cost of Memantine 21mg Oral Capsules (US$), March'2022
  • Figure 8-46: US - Cost of Supply of 100 Capsules & Per Unit Cost of Memantine 21mg Oral Capsules (US$), March'2022
  • Figure 8-47: US - Cost of Supply of 30, 90, 100 & 500 Capsules of Memantine 28mg Oral Capsules (US$), March'2022
  • Figure 8-48: US - Cost of Supply of 49 Kits & Per Unit Cost of Memantine Kit (US$), March'2022
  • Figure 8-49: US - Cost of Supply of 240ml & Per Unit Cost of Memantine Oral Solution (US$), March'2022
  • Figure 8-50: US - Cost of Supply of 360ml & Per Unit Cost of Memantine Oral Solution (US$), March'2022
  • Figure 8-51: US - Cost of Supply of 50, 60, 100, 500 & 1000 Tablets of Memantine 5mg (US$), March'2022
  • Figure 8-52: US - Cost of Supply of 50, 60, 100, 500, 1000 & 3000 Tablets of Memantine 10mg (US$), March'2022
  • Figure 8-53: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Memantine 10mg Oral Tablets (GBP/US$), March'2022
  • Figure 8-54: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Memantine 20mg Oral Tablets (GBP/US$), March'2022
  • Figure 8-55: UK - Cost of Supply of 100ml & Per Unit Cost of Memantine 10mg/ml Oral Solution (GBP/US$), March'2022
  • Figure 8-56: Memantine Tablet - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-57: Memantine XR - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-58: US - Cost of Supply of 100 Tablets & Per Unit Price of Ergoloid MesylatesTablet (US$), March'2022
  • Figure 8-59: Ergoloid Mesylates - Daily, Monthly & Annual Treatment Cost (US$), March'2022
  • Figure 9-1: US - Suvorexant Approval Year by Indication
  • Figure 9-2: US - Belsmora Patent 1 Approval & Expiration Year
  • Figure 9-3: US - Belsmora Patent 2 Approval & Expiration Year
  • Figure 9-4: US - Cost of Supply of 30 Tablets & Per Unit Cost of Belsomra Oral Tablets (US$), March'2022
  • Figure 9-5: Belsomra - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 9-6: Global - Belsomra Annual Sales by Year (US$ Million), 2020 & 2021
  • Figure 9-7: Global - Belsomra Quarterly Sales (US$ Million), 2021
  • Figure 9-8: Global - Belsomra Quarterly Sales (US$ Million), 2020
  • Figure 9-9: UK - Cost of Supply of 100 Vitamin E Tablets by Strength (US$/GBP), March'2022
  • Figure 9-10: Vitamin E - Recommended Minimum & Maximum Dose for Adults (International Units)
  • Figure 9-11: India - Cost of Supply of 10 Tablets & Per Unit Cost of Arcalion Oral Tablet (INR/US$), March'2022
  • Figure 9-12: Sulbutamine - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 9-13: Sulbutamine - Recommended Minimum & Maximum Tablets (mg/day)
  • Figure 9-14: Sulbutamine - Average Daily, Monthly & Annual Cost of Treatment (US$); March'2022
  • Figure 9-15: UK - Cost of 60 Tablets & Per Unit Cost of Nootropil 1200mg Tablet (GBP/US$), March'2022
  • Figure 9-16: UK - Cost of 90 Tablets & Per Unit Cost of Nootropil 800mg Tablet (GBP/US$), March'2022
  • Figure 9-17: Piracetam - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 9-18: Sodium Oligomannate - Average Number of Capsules Required in Day & Month
  • Figure 9-19: Sodium Oligomannate - Average Daily, Monthly & Annual Cost of Treatment (Yuan/US$), March'2022
  • Figure 10-1: Global - Number of Alzheimer's Drugs in Clinical Trials by Biomarker, 2022 till 2028
  • Figure 10-2: Global - Number of Alzheimer's Drugs in Clinical Trials by Formulation, 2022 till 2028
  • Figure 10-3: Global - Number of Alzheimer's Drugs in Clinical Trials by Organization, 2022 till 2028
  • Figure 10-4: Global - Number of Alzheimer's Drugs in Clinical Trials by Phase, 2022 till 2028
  • Figure 10-5: Global - Number of Alzheimer's Drugs in Clinical Trials by Patient Segment, 2022 till 2028